LBT Innovations shares on a tear after artificial intelligence tech gets US approval

Sean Gallup/Getty Images.

Shares in Adelaide-based medtech LBT Innovations soared after the US Food and Drug Administration (FDA) approved the company’s artificial intelligence imaging and software for use as a medical device.

A short time ago, its shares were up 55% to $0.295.

Clever Culture Systems AG, the Swiss-based joint venture between LBT Innovations Limited and Hettich AG, received clearance of its APAS (Automated Plate Assessment System) as a Class II medical device.

APAS is an artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation.

This enables the faster diagnosis and reporting of infectious diseases.

“FDA clearance is a fitting tribute to the many years of painstaking work by LBT’s staff and partners, who together have made our shared vision a reality,” says Brent Barnes, CEO of LBT Innovations.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.